Pandey Lab

Janardan Pandey

Janardan P. Pandey, Ph.D.
Microbiology & Immunology

1972 Ph.D., University of Wisconsin, Madison

Contact Info
Tel: 843-792-4360
BSB 753A-B

Research Interests

The primary focus of my laboratory is directed towards understanding the mechanisms underlying the involvement of immunoglobulin Fc (GM) and Fc gamma receptor genes in immunity to various neurological, malignant, and infectious diseases. These studies are supported in part by grants and contracts from the National Institutes of Health and the Department of Defense.

Recent Publications

1. Pandey JP, Olsson J, Weidung B, Kothera RT, Johansson A, Eriksson S, Hallmans G, Elgh F, Lövheim H. An Ig  marker genotype is a strong risk factor for Alzheimer’s disease, independent of apolipoprotein E 4 genotype. J Immunol 2020; 205:1318-1322.

2. Costa AS, Agostini S, Guerini FR, Mancuso R, Pandey JP. Relation between FCGRIIB rs1050501 and HSV-1 specific IgG antibodies in Alzheimer’s disease. J Transl Med 2020; 18(1):325.

3. Pandey JP, Nietert PJ, Kothera RT, Barnes LL, Bennett DA. Interactive effects of HLA and GM alleles on the development of Alzheimer’s disease. Neurol Genet 2021; 7:e565.

4. Pandey JP, Namboodiri AM, Nietert PJ, Knowles MR, Pace RG, Pier GB. Immunoglobulin GM and KM allotypes are associated with antibody responses to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients. J Cyst Fibros 2021; 20:1080-1084.

5. Pandey JP, Namboodiri AM, Nietert PJ, Barnes LL, Bennett DA. Inhibitory Fc receptor and paired immunoglobulin type 2 receptor alpha genotypes in Alzheimer’s disease. J Alzheimer’s Dis 2021; 84:965-968.

6. Casazza JP,-------Pandey JP,-----Mascola JR; VRC 603 Study Team. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med 2022; 28:1022-1030.

7. Lopatko Lindman K, ----, Pandey JP, --- Lövheim H. PILRA polymorphism modifies the effect of APOE4 and GM17 on Alzheimer’s disease risk. Sci Rep 2022 Aug 2;12(1):13264.

8. Pandey JP, Agostini S, Namboodiri AM, Mancuso R, Guerini FR, Meloni M, Costa AS. Immunoglobulin  chain allotypes and humoral immunity to HSV1 in Parkinson’s disease. J Neuroimmunol 2022; 371: 577948.

9. Pandey JP. IgG3 constant-region GM ( marker) allotypes could influence the neutralizing potency of anti-SARS-CoV-2 monoclonal antibodies. Proc Natl Acad Sci USA 2022; 119 (6) e2119380119.

10. Pandey JP. Immunoglobulin  marker genes as effect modifiers of Epstein-Barr virus-multiple sclerosis association. Immunology 2023; 169:242-244.

11. Pandey JP. Consideration of C1q and FcRn binding to allotypically disparate IgG3 could aid in engineering more efficacious anti-SARS-CoV-2 mAbs. Proc Natl Acad Sci USA 2023; 120 (22) e2306078120.

Research Support

1R01AG080451 8/1/2023-4/30/2028
Immunoglobulin Genes and Immunity to HSV1 in Alzheimer’s Disease
Role: PI

DOD/Rare Cancer Concept Award
HT9425-23-1-0504 1/15/2023-1/14/2024
Epistatic Effects of Fcγ (GM) and FcγR Genes on the ADCC of EGFR-Overexpressing Osteosarcoma Cells
Role: PI

1R21HL167662 4/1/2023-1/31/2025
IGHG Genes (GM Allotypes) and Anti-CMV (UL70) Antibody Responses as Prognostic Markers for Chronic Graft-Versus-Host-Disease
Role: PI

1R21EY034167 9/1/2022-8/31/2024
FCGRIIIA and IGHG (GM) Genotypes and Immunity to HSV1 in Herpes Stromal Keratitis
Role: PI

DOD/PRMRP 1/15/2022-1/14/2025
Racial Disparity in Covid-19 and the Role of Immunoglobulin Genes
Role: PI

Leidos/NIH 04/01/2016-8/30/2024
NCI contract 75N91019D00024 (Task order 75N91020F00006)
GM Allotypes and the pharmacokinetics of broadly neutralizing HIV1 human monoclonal antibodies
Role: PI

Top of Page